Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$317.50
-2.0%
$297.55
$205.87
$333.70
$42.26B0.23853,154 shs972,968 shs
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$7.36
-6.6%
$6.92
$3.76
$12.06
$1.20B1.746.42 million shs10.79 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.75
+1.9%
$13.13
$8.02
$15.78
$7.19B1.675.06 million shs6.01 million shs
Galapagos NV stock logo
GLPG
Galapagos
$28.81
+1.1%
$27.91
$22.36
$31.23
$1.88B0.07250,274 shs192,860 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$9.33
$10.62
$9.20
$16.05
$4.38B0.491,293 shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-2.05%-1.42%+5.54%+30.51%+24.46%
Array Technologies, Inc. stock logo
ARRY
Array Technologies
-6.60%+10.84%-1.87%+62.47%-24.12%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.86%+2.15%+5.77%+56.58%+5.73%
Galapagos NV stock logo
GLPG
Galapagos
+1.12%+3.37%+3.89%+18.36%+12.06%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%-10.80%-20.26%-32.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.1176 of 5 stars
2.44.00.04.32.82.50.6
Array Technologies, Inc. stock logo
ARRY
Array Technologies
3.5253 of 5 stars
3.23.00.00.02.70.03.1
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.3591 of 5 stars
1.34.00.00.31.91.71.3
Galapagos NV stock logo
GLPG
Galapagos
0.3144 of 5 stars
0.83.00.00.01.30.00.6
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.80
Moderate Buy$341.917.69% Upside
Array Technologies, Inc. stock logo
ARRY
Array Technologies
2.48
Hold$9.1323.98% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.333.95% Upside
Galapagos NV stock logo
GLPG
Galapagos
1.50
Reduce$25.33-12.07% Downside
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARRY, ALNY, OPHLF, GLPG, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$328.00 ➝ $384.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/30/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.00
6/27/2025
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00
6/26/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$320.00 ➝ $377.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/24/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.00
6/20/2025
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.00
6/20/2025
Array Technologies, Inc. stock logo
ARRY
Array Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$12.00 ➝ $13.00
6/20/2025
Array Technologies, Inc. stock logo
ARRY
Array Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $8.00
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.25B18.41N/AN/A$0.52 per share610.58
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$915.81M1.23$2.65 per share2.78($0.78) per share-9.44
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.65$2.30 per share6.42$12.33 per share1.20
Galapagos NV stock logo
GLPG
Galapagos
$288.19M6.59$0.73 per share39.24$47.57 per share0.61
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.20B1.37$1.08 per share8.66$11.07 per share0.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A356.74N/A-11.49%-510.31%-6.48%7/30/2025 (Estimated)
Array Technologies, Inc. stock logo
ARRY
Array Technologies
-$240.39M-$1.85N/A10.510.60-21.21%1,227.67%9.83%8/14/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.9316.572.838.43%7.54%3.57%8/6/2025 (Estimated)
Galapagos NV stock logo
GLPG
Galapagos
$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$330.31M$0.7013.33N/A10.24%6.20%4.66%7/28/2025 (Estimated)

Latest ARRY, ALNY, OPHLF, GLPG, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.34N/AN/AN/A$80.13 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Array Technologies, Inc. stock logo
ARRY
Array Technologies
$0.09$0.13+$0.04$0.02$264.14 million$302.36 million
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
4/23/2025Q1 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Array Technologies, Inc. stock logo
ARRY
Array Technologies
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Galapagos NV stock logo
GLPG
Galapagos
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8.88
3.04
2.98
Array Technologies, Inc. stock logo
ARRY
Array Technologies
N/A
2.39
1.93
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Galapagos NV stock logo
GLPG
Galapagos
N/A
7.95
7.86
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.13
3.07
2.56
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,230130.39 million128.82 millionOptionable
Array Technologies, Inc. stock logo
ARRY
Array Technologies
1,021152.55 million151.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Galapagos NV stock logo
GLPG
Galapagos
1,31065.90 millionN/AOptionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
3,853469.71 millionN/ANot Optionable

Recent News About These Companies

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval
Equillium keeps equilibrium in GVHD after Ono no-go
Ono, Boehringer add to cancer pipelines with licensing deals
Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical
Nectar Classic Hybrid Mattress review 2024
The best Plank mattresses of 2024, tested and reviewed
MCLA-145 by Merus for Merkel Cell Carcinoma: Likelihood of Approval

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$317.50 -6.63 (-2.05%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$316.51 -0.99 (-0.31%)
As of 08:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Array Technologies stock logo

Array Technologies NASDAQ:ARRY

$7.36 -0.52 (-6.60%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.05 (+0.75%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products portfolio includes DuraTrack HZ v3, a single axis tracker; Array STI H250 that delivers a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance energy production. Array Technologies, Inc. was incorporated in 1987 and is headquartered in Albuquerque, New Mexico.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.75 +0.28 (+1.94%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$14.82 +0.07 (+0.47%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Galapagos stock logo

Galapagos NASDAQ:GLPG

$28.81 +0.32 (+1.12%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$28.95 +0.14 (+0.49%)
As of 08:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$9.33 0.00 (0.00%)
As of 07/3/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.